NADPH oxidase has recently been identified as a promising new therapeutic target in ALS. Genetic deletion of NADPH oxidase (Nox2) in the transgenic SOD1 G93A mutant mouse model of ALS was reported to increase survival remarkably by 97 days. Furthermore, apocynin, a widely used inhibitor of NADPH oxidase, was observed to dramatically extend the survival of the SOD1 G93A ALS mice even longer to 113 days (Harraz et al. J Clin Invest 118: 474, 2008) . Diapocynin, the covalent dimer of apocynin, has been reported to be a more potent inhibitor of NADPH oxidase. We compared the protection of diapocynin to apocynin in primary cultures of SOD1
G93A
-expressing motor neurons against nitric oxide-mediated death. Diapocynin, 10 μM, provided significantly greater protection compared to apocynin, 200 μM, at the lowest statistically significant concentrations. However, administration of diapocynin starting at 21 days of age in the SOD1 G93A -ALS mouse model did not extend lifespan. Repeated parallel experiments with apocynin failed to yield protection greater than a 5-day life extension in multiple trials conducted at two separate institutions. The maximum protection observed was an 8-day extension in survival when diapocynin was administered at 100 days of age at disease onset. HPLC with selective ion monitoring by mass spectrometry revealed that both apocynin and diapocynin accumulated in the brain and spinal cord tissue to low micromolar concentrations. Diapocynin was also detected in the CNS of apocynin-treated mice. The failure to achieve significant protection with either apocynin or diapocynin raises questions about the utility for treating ALS patients.
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Introduction
Recently, a dramatic extension has been reported on the lifespan in the high expressing SOD1 G93A mouse model of amyotrophic lateral sclerosis (ALS). Disruption of NADPH oxidase (Nox), either as genetic knockouts or through pharmacological inhibition, extended the survival of the ALS mice by about 100 days-the greatest protection ever observed in this animal model (Marden et al., 2007; Harraz et al., 2008) . The evidence implicating a role for Nox in the SOD1 G93A mouse model is particularly intriguing because Nox catalyzes the formation of superoxide from NADPH and oxygen while SOD1 is the primary cytosolic scavenger of superoxide. The Nox family, which includes seven different known isoforms expressed in various tissue, consists of membrane-associated enzymes that require several cytosolic subunits to bind in order to activate superoxide formation (Bedard and Krause, 2007; Lambeth, 2004) . Nox2 (gp91 phox ) is primarily found in phagocytes and involved in host defense. In the central nervous system (CNS), Nox2 is the predominant isoform found in microglia, astrocytes and neuron cells. Although most highly expressed in the colon, Nox1 is also expressed in the CNS (Sorce and Krause, 2009). Marden et al. (2007) reported homozygous knockouts of both Nox1 and Nox2 substantially increased the survival of the hybrid B6SJL transgenic SOD1 G93A mouse model of ALS with the greatest effect in the Nox2 knockout. Nox2 extended life by 97 days, whereas the Nox1 knockout increased survival by 33 days. The heterozygous Nox2 and Nox1 knockout ALS mice also showed an increased survival of 54 days and 11 days, respectively. Furthermore, a redox-dependent activation of rac1 modulated by SOD1 was identified for Nox activation (Harraz et al., 2008) . This interaction was disrupted by
